Royal Bank of Canada Increases Position in ADMA Biologics Inc $ADMA

Royal Bank of Canada increased its holdings in ADMA Biologics Inc (NASDAQ:ADMA) by 448.8% in the 1st quarter, HoldingsChannel.com reports. The fund owned 929,326 shares of the biotechnology company’s stock after buying an additional 759,984 shares during the period. Royal Bank of Canada’s holdings in ADMA Biologics were worth $8,373,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Summit Securities Group LLC purchased a new position in ADMA Biologics in the fourth quarter worth $29,000. Optima Capital LLC purchased a new stake in shares of ADMA Biologics during the 4th quarter valued at $36,000. iSAM Funds UK Ltd bought a new stake in shares of ADMA Biologics during the 3rd quarter worth $34,000. Morse Asset Management Inc purchased a new position in shares of ADMA Biologics in the 4th quarter worth about $44,000. Finally, Nkcfo LLC purchased a new position in shares of ADMA Biologics in the 4th quarter worth about $47,000. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics News Summary

Here are the key news stories impacting ADMA Biologics this week:

• Neutral Sentiment: The August 10, 2026 deadline allows investors who purchased ADMA securities between August 9, 2024, and March 25, 2026, to apply to become lead plaintiff. The notices state that eligible investors may pursue compensation through a contingency-fee arrangement, but the announcements do not establish that ADMA violated securities laws. Rosen Law Firm deadline notice
• Negative Sentiment: Hagens Berman said the lawsuit concerns alleged misrepresentations about ADMA’s financial condition, revenue recognition, inventory distribution and business practices. The allegations could increase legal costs, create potential liability and undermine investor confidence if they proceed. Hagens Berman class-action notice
• Negative Sentiment: Rosen, Faruqi & Faruqi, DJS Law Group and Schall, Brown & Schwartz separately promoted the pending securities action and encouraged affected shareholders to contact them. The unusually large number of substantially similar notices may amplify short-term headline pressure on ADMA, although they largely repeat the same underlying litigation information. Faruqi & Faruqi class-action deadline DJS Law Group lawsuit notice

Analyst Upgrades and Downgrades

ADMA has been the subject of several research reports. Canaccord Genuity Group reduced their price target on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a research report on Thursday, June 18th. Mizuho dropped their target price on shares of ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 15th. Wall Street Zen downgraded shares of ADMA Biologics from a “buy” rating to a “hold” rating in a research report on Monday, May 4th. Finally, Zacks Research lowered shares of ADMA Biologics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, August 4th. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $18.67.

ADMA Biologics Stock Down 1.5%

ADMA stock opened at $9.75 on Tuesday. The stock has a 50-day simple moving average of $8.67 and a two-hundred day simple moving average of $11.21. ADMA Biologics Inc has a twelve month low of $7.21 and a twelve month high of $20.46. The firm has a market capitalization of $2.26 billion, a PE ratio of 13.93 and a beta of 0.74. The company has a quick ratio of 3.81, a current ratio of 6.97 and a debt-to-equity ratio of 0.49.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.16. ADMA Biologics had a net margin of 32.98% and a return on equity of 40.17%. The firm had revenue of $124.39 million for the quarter, compared to the consensus estimate of $125.34 million. During the same period in the prior year, the firm posted $0.14 earnings per share. The company’s revenue for the quarter was up 2.0% on a year-over-year basis. On average, equities analysts predict that ADMA Biologics Inc will post 0.76 EPS for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.